Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Aug;36(8):1788–1790. doi: 10.1128/aac.36.8.1788

In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.

W A Agger 1, S M Callister 1, D A Jobe 1
PMCID: PMC192050  PMID: 1416868

Abstract

We determined the in vitro susceptibilities of eight Borrelia burgdorferi isolates to five oral cephalosporins. MICs for B. burgdorferi 297 were 23 micrograms/ml (cephalexin), 45 micrograms/ml (cefadroxil), 91 micrograms/ml (cefaclor), 0.13 microgram/ml (cefuroxime), 0.8 microgram/ml (cefixime), and 0.02 microgram/ml (ceftriaxone). When B. burgdorferi isolates were exposed to concentrations twice the MIC of cefuroxime, cefixime, or ceftriaxone, at least 72 h of incubation was required to kill 99% of the organisms.

Full text

PDF
1788

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbour A. G. Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med. 1984 Jul-Aug;57(4):521–525. [PMC free article] [PubMed] [Google Scholar]
  2. Barbour A. G., Tessier S. L., Todd W. J. Lyme disease spirochetes and ixodid tick spirochetes share a common surface antigenic determinant defined by a monoclonal antibody. Infect Immun. 1983 Aug;41(2):795–804. doi: 10.1128/iai.41.2.795-804.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berger B. W. Treatment of erythema chronicum migrans of Lyme disease. Ann N Y Acad Sci. 1988;539:346–351. doi: 10.1111/j.1749-6632.1988.tb31868.x. [DOI] [PubMed] [Google Scholar]
  4. Burgdorfer W., Barbour A. G., Hayes S. F., Benach J. L., Grunwaldt E., Davis J. P. Lyme disease-a tick-borne spirochetosis? Science. 1982 Jun 18;216(4552):1317–1319. doi: 10.1126/science.7043737. [DOI] [PubMed] [Google Scholar]
  5. Callister S. M., Case K. L., Agger W. A., Schell R. F., Johnson R. C., Ellingson J. L. Effects of bovine serum albumin on the ability of Barbour-Stoenner-Kelly medium to detect Borrelia burgdorferi. J Clin Microbiol. 1990 Feb;28(2):363–365. doi: 10.1128/jcm.28.2.363-365.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Callister S. M., Schell R. F., Lovrich S. D. Lyme disease assay which detects killed Borrelia burgdorferi. J Clin Microbiol. 1991 Sep;29(9):1773–1776. doi: 10.1128/jcm.29.9.1773-1776.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dattwyler R. J., Halperin J. J. Failure of tetracycline therapy in early Lyme disease. Arthritis Rheum. 1987 Apr;30(4):448–450. doi: 10.1002/art.1780300414. [DOI] [PubMed] [Google Scholar]
  8. Dattwyler R. J., Halperin J. J., Pass H., Luft B. J. Ceftriaxone as effective therapy in refractory Lyme disease. J Infect Dis. 1987 Jun;155(6):1322–1325. doi: 10.1093/infdis/155.6.1322. [DOI] [PubMed] [Google Scholar]
  9. Dattwyler R. J., Halperin J. J., Volkman D. J., Luft B. J. Treatment of late Lyme borreliosis--randomised comparison of ceftriaxone and penicillin. Lancet. 1988 May 28;1(8596):1191–1194. doi: 10.1016/s0140-6736(88)92011-9. [DOI] [PubMed] [Google Scholar]
  10. Dattwyler R. J., Volkman D. J., Luft B. J., Halperin J. J., Thomas J., Golightly M. G. Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi. N Engl J Med. 1988 Dec 1;319(22):1441–1446. doi: 10.1056/NEJM198812013192203. [DOI] [PubMed] [Google Scholar]
  11. Johnson R. C., Kodner C. B., Jurkovich P. J., Collins J. J. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents. Antimicrob Agents Chemother. 1990 Nov;34(11):2133–2136. doi: 10.1128/aac.34.11.2133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Johnson R. C., Kodner C., Russell M. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob Agents Chemother. 1987 Feb;31(2):164–167. doi: 10.1128/aac.31.2.164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Luft B. J., Volkman D. J., Halperin J. J., Dattwyler R. J. New chemotherapeutic approaches in the treatment of Lyme borreliosis. Ann N Y Acad Sci. 1988;539:352–361. doi: 10.1111/j.1749-6632.1988.tb31869.x. [DOI] [PubMed] [Google Scholar]
  14. Morgan J. R., Paull A., O'Sullivan M., Williams B. D. The penetration of ceftriaxone into synovial fluid of the inflamed joint. J Antimicrob Chemother. 1985 Sep;16(3):367–371. doi: 10.1093/jac/16.3.367. [DOI] [PubMed] [Google Scholar]
  15. Steere A. C., Green J., Schoen R. T., Taylor E., Hutchinson G. J., Rahn D. W., Malawista S. E. Successful parenteral penicillin therapy of established Lyme arthritis. N Engl J Med. 1985 Apr 4;312(14):869–874. doi: 10.1056/NEJM198504043121401. [DOI] [PubMed] [Google Scholar]
  16. Steere A. C., Grodzicki R. L., Kornblatt A. N., Craft J. E., Barbour A. G., Burgdorfer W., Schmid G. P., Johnson E., Malawista S. E. The spirochetal etiology of Lyme disease. N Engl J Med. 1983 Mar 31;308(13):733–740. doi: 10.1056/NEJM198303313081301. [DOI] [PubMed] [Google Scholar]
  17. Steere A. C., Hutchinson G. J., Rahn D. W., Sigal L. H., Craft J. E., DeSanna E. T., Malawista S. E. Treatment of the early manifestations of Lyme disease. Ann Intern Med. 1983 Jul;99(1):22–26. doi: 10.7326/0003-4819-99-1-22. [DOI] [PubMed] [Google Scholar]
  18. Steere A. C., Pachner A. R., Malawista S. E. Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. Ann Intern Med. 1983 Dec;99(6):767–772. doi: 10.7326/0003-4819-99-6-767. [DOI] [PubMed] [Google Scholar]
  19. Weber K., Preac-Mursic V., Neubert U., Thurmayr R., Herzer P., Wilske B., Schierz G., Marget W. Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans. Ann N Y Acad Sci. 1988;539:324–345. doi: 10.1111/j.1749-6632.1988.tb31867.x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES